OTC · Medical - Diagnostics & Research

Interpace Biosciences, Inc. (IDXG) Stock

$1.50 -8.13% OTC: IDXG Healthcare

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk.

Valuation

MetricValue
Price$1.50
Market Cap$41.48M
P/E Ratio0.29
P/B Ratio1.48
P/S Ratio1.14
EPS (TTM)$5.17
52-Week High$2.40
52-Week Low$0.77
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE215.31%
ROA70.79%
ROCE11.47%
Gross Margin62.53%
Operating Margin9.32%
Net Margin65.25%
Debt/Equity0.05
Current Ratio2.51

Annual Financials (USD)

Metric20212022202320242025
Revenue$41.0M$32.0M$40.0M$47.0M$39.0M
Operating Profit$-12.0M$-4.0M$3.0M$8.0M$4.0M
Net Profit$-15.0M$-6.0M$1.0M$7.0M$25.0M
EPS$-3.57$-1.38$0.18$0.40$0.89
Op Margin-28.4%-12.1%7.0%17.3%10.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$38.0M$16.0M$13.0M$15.0M$34.0M
Total Liabilities$81.0M$79.0M$28.0M$17.0M$11.0M
Cash$3.0M$5.0M$3.0M$1.0M$3.0M
Borrowings$14.0M$16.0M$11.0M$6.0M$1.0M

Latest News

Interpace Biosciences Announces First Quarter 2026 Financial and Business Results GlobeNewswire · May 12, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-9.0M$-8.0M$4.0M$5.0M$6.0M
Investing Cash Flow$-1.0M$12.0M$-1.0M$-2.0M$-1.0M
Financing Cash Flow$0$0$-3.0M$0$0
Net Cash Flow$0$2.0M$-1.0M$-2.0M$1.0M
Free Cash Flow$-9.0M$-8.0M$3.0M$4.0M$5.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA9.80
FCF Yield10.56%
Quick Ratio2.27
Interest Coverage37.53
Return 1Y—
Return 3Y—
Return 5Y—

Ownership

Insiders Held85.18%
Institutions Held0.00%
Institutions Float Held0.00%
Institutional HolderSharesReport Date
John Hancock Var Ins Tr-Total Stock Market Index Tr2762022-06-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVCRFAvricore Health Inc. $0.03 +0.00% -2.82 $2.53M 0.00%
CPIVFCaptiva Verde Wellness Corp. $0.02 -8.54% -6.86 $4.58M 0.00%
ICBUiMD Companies, Inc. $0.00 — -4.40 $2.17M 0.00%
LIFDLFTD Partners Inc. $0.20 -2.50% -0.10 $2.89M 0.00%
RMSLREMSleep Holdings, Inc. $0.00 — 0.00 $2.71M 0.00%

About Interpace Biosciences, Inc.

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic test for pancreatic cysts and solid lesions within the pancreaticobiliary system. This test, powered by the proprietary PathFinderTG platform, assists medical professionals in more accurately determining the risk of pancreaticobiliary cancers. It also offers PanDNA, a molecular-only variant of PancraGEN, which delivers insights into a select number of diagnostic markers. For thyroid health, the company provides ThyGeNEXT, an oncogenic mutation panel designed to identify malignant thyroid nodules. Additionally, ThyraMIR evaluates thyroid nodules for malignancy risk through the application of its proprietary microRNA gene-expression assay. Furthermore, RespriDx is a genomic diagnostic tool that aids clinicians in distinguishing between metastatic and recurrent lung cancer. Interpace Biosciences further supports the pharmaceutical and biotechnology sectors with services including pharmacogenomics testing, genotyping, biorepository solutions, and various custom scientific offerings. Its clientele primarily consists of physicians, hospitals, and clinics. Previously operating as Interpace Diagnostics Group, Inc., the company adopted its current name, Interpace Biosciences, Inc., in November 2019. Founded in 1986, its corporate headquarters are located in Parsippany, New Jersey.

Interpace Biosciences, Inc. is headquartered in US.

Interpace Biosciences, Inc. (IDXG) stock trades at $1.50 with a market capitalization of $41.48M. The stock is valued at a price-to-earnings (P/E) ratio of 0.29, price-to-book of 1.48, price-to-sales of 1.14. Over the past 52 weeks the stock has ranged between $0.77 and $2.40, and currently trades 37.5% below its 52-week high.

On profitability, Interpace Biosciences, Inc. generates a return on equity (ROE) of 215.31% — well above the market average, a sign of a high-quality business, return on capital employed of 11.47%, an operating margin of 9.32%, a net profit margin of 65.25%.

Official website: www.interpace.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides